PAIB-SO sec-butyl

PAIB-SO sec-butyl (phenyl 4-(3-(sec-butyl)-2-oxoimidazolidin-1-yl)benzenesulfonate) is a synthetic small molecule belonging to the phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonate (PAIB-SO) family of antimitotic prodrugs. Developed by researchers at Université Laval, PAIB-SOs are designed as tumor-selective chemotherapeutic agents that undergo bioactivation via CYP1A1-mediated N-dealkylation into highly potent antimitotic counterparts known as phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates (PIB-SOs), which disrupt microtubule integrity and arrest the cell cycle in the G2/M phase. However, structure-activity relationship (SAR) studies have shown that the sec-butyl substituted derivative (PAIB-SO sec-butyl) is not efficiently metabolized by CYP1A1, leading to a loss of selectivity toward breast cancer cells and only moderate, micromolar-range antiproliferative activity.

Other names

3,4,5-trimethoxyphenyl 4-(3-(sec-butyl)-2-oxoimidazolidin-1-yl)benzenesulfonatephenyl 4-(3-(sec-butyl)-2-oxoimidazolidin-1-yl)benzenesulfonatephenyl 4-(3-sec-butyl-2-oxoimidazolidin-1-yl)benzenesulfonatesec-butyl PAIB-SO